Evidence map›Paper›PMID 29431617›Full record

ArticleMolecular cancer research : MCR2018

Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma.

Shirin Ilkhanizadeh, Hanna Sabelström, Yekaterina A Miroshnikova, Aaron Frantz, Wen Zhu, Aurora Idilli, Jon N Lakins, Christin Schmidt, David A Quigley, Trenten Fenster and 14 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer research : MCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04117672 phase2recruitingnot on this mapstarted 2020, after this paper: background citation

Evaluation of Antisecretory Factor in Treatment of Severe Traumatic Brain Injury With Multimodal Monitoring

TypeinterventionalSponsorPeter SiesjöRan2020 to 2027Enrolled20ConditionsTraumatic Brain InjuryArmsSalovum, Placebo egg yolk powder
NCT05339230 naunknown statusnot on this mapstarted 2020, after this paper: background citation

A Randomized Phase 2 and Pilot Pharmacodynamic Trial Investigating the Effect of Salovum™ and SPC-flakes on Dihydropyrimidine Induced Gastrointestinal Toxicity and Tumour Perfusion in Colorectal Cancer

TypeinterventionalSponsorUppsala University HospitalRan2020 to 2025Enrolled73ConditionsDihydropyrimidine Induced Gastrointestinal Toxicity in Colorectal CancerArmsSalovum and SPC-flakes active or placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Anti-Inflammatory Substances in Wheat Malt Inducing Antisecretory Factor.Plant foods for human nutrition (Dordrecht, Netherlands) · 2019
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Shirin Ilkhanizadeh *Department of Neurology, University of California, San Francisco, San Francisco, California.
Hanna Sabelström *Department of Neurology, University of California, San Francisco, San Francisco, California.
Yekaterina A MiroshnikovaDepartment of Surgery, University of California, San Francisco, San Francisco, California.
Aaron FrantzDepartment of Neurology, University of California, San Francisco, San Francisco, California.
Wen ZhuDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Aurora IdilliInstitute of Biophysics, CNR and FBK, Trento, Italy.
Jon N LakinsDepartment of Surgery, University of California, San Francisco, San Francisco, California.
Christin SchmidtDepartment of Neurology, University of California, San Francisco, San Francisco, California.
David A QuigleyBrain Tumor Research Center (BTRC) at the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Trenten FensterDepartment of Neurology, University of California, San Francisco, San Francisco, California.
Edith YuanDepartment of Neurology, University of California, San Francisco, San Francisco, California.
Jacqueline R TrzeciakDepartment of Neurology, University of California, San Francisco, San Francisco, California.
Supna SaxenaDepartment of Neurology, University of California, San Francisco, San Francisco, California.
Olle R LindbergBrain Tumor Research Center (BTRC) at the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Janna K MouwDepartment of Surgery, University of California, San Francisco, San Francisco, California.
Jason A BurdickDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania.
Sergey MagnitskyDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Mitchel S BergerBrain Tumor Research Center (BTRC) at the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Joanna J PhillipsBrain Tumor Research Center (BTRC) at the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Daniele ArosioInstitute of Biophysics, CNR and FBK, Trento, Italy.
Dandan SunDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Valerie M WeaverDepartment of Surgery, University of California, San Francisco, San Francisco, California.
William A WeissDepartment of Neurology, University of California, San Francisco, San Francisco, California.
Anders I PerssonDepartment of Neurology, University of California, San Francisco, San Francisco, California. Anders.Persson@ucsf.edu.

Funding

Integrating targeted and immunotherapy to treat genetically heterogeneous cancersU01CA217864 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN, KRUMMEL, MATTHEW F · 2017 to 2021
$5.1M
The vascular niche in glioma propagation and resistance to therapyU54CA163155 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE, WEAVER, VALERIE MARIE · 2011 to 2015
$4.4M
Tension-Stat3-miR-mediated metastasisR01CA192914 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEEWALDT, VICTORIA L., WEAVER, VALERIE MARIE · 2015 to 2019
$2.9M
Precision Medicine For Pediatric Low-Grade GliomasR01NS091620 · NINDS · DANA-FARBER CANCER INST · PI HAAS-KOGAN, DAPHNE A., RESNICK, ADAM CAIN · 2015 to 2019
$2.6M
Autophagy as a microenvironmental regulator of tumorigenesis and resistanceR01CA188404 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE, DEBNATH, JAYANTA · 2014 to 2018
$2.1M
Na-K-Cl cotransporter in Glioblastoma MultiformeR01NS075995 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUN, DANDAN · 2011 to 2015
$1.8M
Heparan sulfate proteoglycans as critical regulators of brain cancer malignancyR01NS081117 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, JOANNA · 2012 to 2016
$1.7M
Antisecretory factor as a novel therapeutic agent in human glioblastomaR21NS088114 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERSSON, PER ANDERS INGEMAR · 2014 to 2015
$395k
NCI NIH HHS R01 CA188404NCI NIH HHS R01 CA192914NCI NIH HHS U01 CA217864NCI NIH HHS U54 CA163155NINDS NIH HHS R01 NS075995NINDS NIH HHS R01 NS081117NINDS NIH HHS R01 NS091620NINDS NIH HHS R21 NS088114
6 · The paper itself

Abstract

Interstitial fluid pressure (IFP) presents a barrier to drug uptake in solid tumors, including the aggressive primary brain tumor glioblastoma (GBM). It remains unclear how fluid dynamics impacts tumor progression and can be targeted therapeutically. To address this issue, a novel telemetry-based approach was developed to measure changes in IFP during progression of GBM xenografts. Antisecretory factor (AF) is an endogenous protein that displays antisecretory effects in animals and patients. Here, endogenous induction of AF protein or exogenous administration of AF peptide reduced IFP and increased drug uptake in GBM xenografts. AF inhibited cell volume regulation of GBM cells, an effect that was phenocopied

Indexed as

AnimalsCell Line, TumorCell ProliferationCell SizeDisease ProgressionGlioblastomaHumansMiceMice, Nude

Identifiers

PMID29431617
PMCPMC5932284

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.